NEUWAVE Microwave Ablation System: Ethicon Launches Global Registry to Collect Real-World Data

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

March 25, 2019

NEUWAVE Microwave Ablation System was announced today by Johnson & Johnson Medical Devices Companies.* Ethicon** has launched a new global registry to collect and analyze real-world data on patients with soft tissue liver lesions ablated with the company’s NEUWAVE Microwave Ablation System.  The announcement was made at the annual meeting of the Society of Interventional Radiology (SIR 2019).

The company reports the multicenter, observational registry will follow approximately 1,500 patients worldwide for a total of five years from the date of their first liver ablation procedure with the NEUWAVE System, a minimally invasive microwave ablation technology that uses heat transmitted through image-guided needle-like probes to destroy soft tissue lesions.

In addition, real-world data will be collected from up to 30 centers throughout the world on the technical aspects of the procedure including ablation time under varying liver tissue and lesion conditions. Efficacy and other outcome data will also be documented and assessed at various time points over the course of the study.

“The goal of the registry is to systematically and comprehensively develop ablation parameter guidance for the microwave ablation of liver lesions with the NEUWAVE System,” said Dr. Paul Laeseke^, Interventional Radiologist, University of Wisconsin School of Medicine and Public Health, who consulted on the design of the registry. “Microwave ablation is an important treatment option that is increasingly being utilized throughout the world, and this data may provide new insights into factors that are critical for successful outcomes across a range of patients, clinical settings and health care providers. The registry will be an important contribution to our understanding of microwave ablation and support its further adoption.”

The registry will also include data from consenting patients enrolled in other Ethicon-sponsored studies on microwave liver ablation with the NEUWAVE System in Korea and China and a multicenter study that is evaluating the device using NEUWAVE’s Ablation Confirmation Software, which helps physicians identify ablation targets, assess appropriate probe placement and confirm the technical success of each procedure.

“Microwave is the fastest growing ablation modality1 and as this treatment grows, Ethicon is committed to working with clinicians throughout the world to generate robust clinical evidence for the innovative NEUWAVE Microwave Ablation System. This will help inform treatment decisions and improvements in procedural efficiency and patient outcomes,” said Piet Hinoul, Global Head Medical & Clinical Franchise Lead for Ethicon.

The NEUWAVE System, the microwave ablation market leader in the United States,2 is a minimally invasive system that enables physicians to effectively tailor ablations for lesions of varying shapes and sizes with consistency and control.3,4 Studies have shown microwave ablation has strong efficacy and a favorable complication profile.  Most patients leave the hospital the same day with only a bandage at the probe insertion site.5


* The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, vision and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.
** Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates. All other trademarks are the property of their respective owners.
^ Dr. Paul Laeseke is a consultant for Ethicon

1 Millennium Research Group 2015.
2 DRG Data
3 Ex-vivo data available in probe Instructions For Use. See ex-vivo data available in probe Instructions For Use.
4 Laeseke et al. Multiple-Antenna Microwave Ablation: Spatially Distributing Power Improves Thermal Profiles and Reduces Invasiveness. Journal of Interventional Oncology. 2009; 2(2):105-112. Brace et al. Simultaneous Activation of Multiple Microwave Antennas Improves Circularity and Ablation Zone Volume Compared to Sequentially Overlapping Ablations. Presented at conference with accompanying poster, WCIO 2014.
5 J. Horn, et al, Percutaneous Microwave Ablation of Renal Tumors Using a Gas-Cooled 2.4-GHz Probe; Technique and Initial Results.  Journal of Vascular Interventional Radiology 2014; 25:448-453



Related Articles